|
|
 |
Presentazioni del Congresso |
|
|
|
|
| |
|
Abstract |
|
PPT |
|
Biblio |
|
| I sessione Letture Introduttive |
|
|
|
|
|
|
|
|
|
| Linea guida DHHS per pazienti HIV positivi C.V. Fletcher |
|
|
 |
|
 |
|
|
|
| Linea guida EACS per pazienti HIV positivi A. Pozniak |
|
|
|
|
|
|
|
|
| L’epidemiologia dell’HIV in Italia G. Rezza |
|
|
|
|
|
|
|
|
| Le persone HIV positive in Italia: aggiornamenti da POSIT S. Marcotullio |
|
|
|
|
|
|
|
|
| Impatto della terapia per l’infezione da HIV sul sistema sanitario italiano: trend attuali e scenari futuri B. Sfogliarini |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Abstract |
|
PPT |
|
Biblio |
|
| II sessione Quando iniziare |
|
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Americana M. Celesia |
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Europea M. Zaccarelli |
|
|
|
|
|
|
|
|
| I parametri fondamentali per stabilire l’inizio della terapia A. De Luca |
|
|
|
|
|
|
|
|
| Iniziare con CD4>500 cell: vantaggi e svantaggi C. Mussini |
|
|
|
|
|
|
|
|
| Test di resistenza nel naive: costi e benefici M. Andreoni |
|
|
|
|
|
|
|
|
| Il management del paziente advance naive A. Castagna |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Abstract |
|
PPT |
|
Biblio |
|
| III sessione Come iniziare |
| Bibliografia |
| • |
Molina JM, Andrade-Villanueva Jet al. CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet, 2008. 372 (9639): 646-55 |
| • |
Ortiz R, Dejesus E et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008. 22 (12): 1389-97 |
| • |
Smith KY, Patel P et al. HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009. 23 (12): 1547-56 |
| • |
Riddler SA, Haubrich R et al. AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008. 358 (20): 2095-106 |
| • |
Lennox JL, De Jesus E et al. STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009. 374 (9692): 796-806 |
| • |
Sax PE, Tierney C et al. AIDS Clinical Trial Group Study A5202 Team. Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. N Engl J Med 2009. 361 (23): 2230-40 |
| • |
Viro-Immunologic Response to Ritonavir-Boosted or Unboosted Atazanavir in a Large Cohort of Multiply Treated Patients: The CARe Study |
| • |
Murphy RL, da Silva BA, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2008; 9(1): 1-10 |
| • |
730 poster a 96 settimane |
| • |
Poster Heat a 96 settimane |
| • |
730 QD donna |
| • |
Poster Posit Donna |
| • |
van Lunzen J., Pauli R. et al. Frequency of lipodystrophy in a large cross sectional study using either LPV/r or EFV in combination with contemporary nucleoside analogues, Infectious Diseases Van Lunzen Lipo IAS 2009 |
| • |
Galli M., Veglia F. et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003; 34(1): 58-61 8 |
| • |
Murri R Cozzi Lepri A. et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003; 34: 184-190 |
| • |
Guaraldi G., Murri R. et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003; 4(2): 99-106 |
| • |
Duran S., Savès M. et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15(18): 2441-2444 |
| • |
Commissione nazionale per la lotta contro l’AIDS “Aggiornamento delle conoscenze sulla terapia dell’infezione da HIV”, Documento Complementare su Specifiche Materie, febbraio 2008 |
| • |
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009; pp 1-139 |
| • |
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D. HIV Med. 2009 Nov;10(10):591-613 |
| • |
Rosso R, Di Biagio A, et al. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother. 2006 Jun;57(6):1168-71. Epub 2006 Apr 10 |
| • |
Gupta RK, Gibb DM, et al. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis. 2009 Jun;22(3):256-63 |
|
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Americana S. Rusconi |
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Europea S. Lo Caputo |
|
|
|
|
|
|
|
|
| Farmaci raccomandati vs regimi raccomandati G. Carosi |
|
|
|
|
|
|
|
|
| Livelli di esposizione a ritonavir: ruolo del PI rinforzato G. Di Perri |
|
|
|
|
|
|
|
|
| Efficacia a lungo termine dei regimi di 1° linea: evidenze cliniche G. Rizzardini |
|
|
|
|
|
|
|
|
| Management terapeutico della donna in età fertile A. D’Arminio Monforte |
|
|
|
|
|
|
|
|
| Management terapeutico del paziente adolescente R. Rosso |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Abstract |
|
PPT |
|
Biblio |
|
| IV sessione cART switch nel paziente con HIV-RNA controllato |
| Bibliografia |
| • |
Arribas J.R., Delgado R. et al. Lopinavir–Ritonavir Monotherapy Versus Lopinavir–Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis J Acquir Immune Defic Syndr _ Volume 00, Number 0, Month, 2009 |
| • |
Linee guida Spagnole |
| • |
Nunes E.P., Santini de Oliveira M. et al. Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study) HIV CLINICAL TRIALS • 10/6 • NOV-DEC 2009 |
| • |
Pierone G., Mieras J. Seven-Year Follow-Up on Lopinavir/ Ritonavir Monotherapy, Journal of the International Association of Physicians in AIDS Care (JIAPAC OnlineFirst, published on May 4, 2009 |
| • |
Imani mono nel tratto genitale |
| • |
Flammer A.J., Ledergerber B. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons. Heart 2009 |
| • |
King M, Rode R, et al. Adherence-resistance Relationships for Lopinavir/ritonavir (LPV/r)-based Regimens in Treatment-experienced Subjects 17th Conference on Retroviruses and Opportunistic Infections • 16-19 February 2010 • San Francisco Abstract 588 |
| • |
Letendre S.L., van den Brande G. et al. Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid HIV/AIDS • CID 2007:45 (1 December) • 1511 |
| • |
Cameron DW, da Silva BA, et al. A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy. JID 2008:198 (15 July) |
| • |
Pulido F, Arribas JR et al. for the OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavirritonavir and two nucleosides for maintenance therapy of HIV AIDS 2008, 22:F1–F9 |
| • |
Pulido F, Pérez-Valero I et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009;14(2):195-201 |
| • |
Sarmati L, Parisi SG, et al. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. J Med Virol, 2007, 79:880-886 |
| • |
Campo RE, Da Silva BA et al. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75 |
| • |
Mallolas J., Podzamczer D. et al. EfficacyandSafety of SwitchingFromBoosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study J Acquir Immune Defic Syndr _ Volume 00, Number 0, Month 0, 2009 |
|
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Americana G. Marasca |
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Europea R. Maserati |
|
|
|
|
|
|
|
|
| Importanza della potenza dei regimi di induzione sull’outcome dei regimi di mantenimento A. Lazzarin |
|
|
|
|
|
|
|
|
| L’importanza della drug convenience nei regimi di cART di mantenimento S. Bonora |
|
|
|
|
|
|
|
|
| Single agent HAART PI based nel paziente stabile: razionali e modalità d’impiego C.F. Perno |
|
|
|
|
|
|
|
|
| Rischio di fallimento dei regimi di semplificazione: evidenze cliniche M. Andreoni |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Abstract |
|
PPT |
|
Biblio |
|
| V sessione Prevenzione e gestione delle comorbidità non “AIDS-defining” |
|
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Americana P. Bonfanti |
|
|
|
|
|
|
|
|
| Raccomandazioni degli esperti della Comunità Scientifica Europea P. Maggi |
|
|
|
|
|
|
|
|
| Problematiche neurocognitive e neuropsichiatriche nel management della terapia A. Antinori |
|
|
|
|
|
|
|
|
| Impatto della soppressione della carica virale sulla riduzione del rischio cardio-vascolare M. Galli |
|
|
|
|
|
|
|
|
| Tossicità degli inibitori della trascrittasi inversa M. Borderi |
|
|
|
|
|
|
|
|
| Impatto della immunodepressione sullo sviluppo di comorbidità non “AIDS-defining” A. Gori |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
